nib offers genetic testing

In a release, the insurer said women with ovarian cancer were able to access testing in the private health system to work out the best course of treatment.

Patients with a BRCA mutation gene are likely to benefit from the addition of a treatment called PARP inhibitors.

Chief executive Rob Hennin said genomic profiling played an increasing role in the treatment and management of cancer.

“We want to ensure our members have the best possible treatment to help them fight this insidious disease,” Hennin said.

“It’s crucial in the management of cancer, for both public and private patients, that they access the best advice and treatment possible without too much delay.”

The agreement between nib and the New Zealand Family Cancer Service will also help women who do not currently meet the criteria for public regional genetic counselling to access those services in the private health system.

“We have a real opportunity to help women diagnosed with ovarian cancer fund their treatment and be a true health partner, ensuring they get the right treatment for their needs,” Hennin said.

nib members whose policies include surgical cover can take up genetic testing for ovarian cancer throughout 2019, with the trial period to be reviewed at the end of the year.